Letter by Muntané-Carol et al Regarding Article, 'Bioresorbable Vascular Scaffolds for the Treatment of Chronic Total Occlusions: An International Multicenter Registry'

We read with interest the study of Mitomo et al1 reporting the feasibility and safety of chronic total occlusions (CTO) revascularization with everolimus-eluting bioresorbable vascular scaffolds. The authors should be congratulated on the outstanding clinical results at follow-up (453 days); target lesion failure and scaffold thrombosis (ST) rates were zero, despite the high-risk characteristics of the population for late complications, such as ST and in-stent restenosis. There have been concerns regarding the somewhat unpredictable behavior of bioresorbable vascular scaffold, especially with regards to the apparent overall increase in late events. Indeed, the perceived increase in late events might discourage their use in scenarios, such as CTO. However, we …